Bio-Rad Laboratories Class A (BIO) closed at $386.00 on November 11, 2026, down 0.1% from the previous close, on volume of 207,240 shares (30-day average 235,912).
Data as of November 11, 2026.
Bio-Rad Laboratories Earnings Call Signals Cautious Recovery
TipRanks (Wed, 11-Nov 7:24 PM ET)
Bio-Rad Reports Third-Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:15 PM ET)
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Business Wire (Thu, 29-Oct 4:30 PM ET)
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Business Wire (Wed, 14-Oct 9:00 AM ET)
Business Wire (Wed, 16-Sep 9:00 AM ET)
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
Business Wire (Mon, 31-Aug 9:00 AM ET)
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Bio-Rad Laboratories Class A trades on the NYSE stock market under the symbol BIO.
As of November 12, 2026, BIO stock price declined to $375.12 with 52,959 million shares trading.
BIO has a beta of 0.87, meaning it tends to be less sensitive to market movements. BIO has a correlation of 0.09 to the broad based SPY ETF.
BIO has a market cap of $10.12 billion. This is considered a Large Cap stock.
Last quarter Bio-Rad Laboratories Class A reported $656 million in Revenue and $2.65 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.35.
In the last 3 years, BIO traded as high as $396.23 and as low as $211.43.
The top ETF exchange traded funds that BIO belongs to (by Net Assets): IJH, VTI, DFSV, VB, VBR.
BIO has outperformed the market in the last year with a return of +19.7%, while the SPY ETF gained +12.6%. In the last 3 month period, BIO beat the market returning +5.3%, while SPY returned -0.9%. However, in the most recent 2 weeks BIO has underperformed the stock market by returning -2.6%, while SPY returned -1.4%.
BIO support price is $377.58 and resistance is $394.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIO shares will trade within this expected range on the day.
